NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity
- 1 May 2020
- journal article
- research article
- Published by Elsevier BV in Bioorganic Chemistry
- Vol. 98, 103449
- https://doi.org/10.1016/j.bioorg.2019.103449
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- N6-Benzyladenosine Derivatives as Novel N-Donor Ligands of Platinum(II) Dichlorido ComplexesMolecules, 2013
- Farnesyl Diphosphate Synthase Inhibitors from In Silico ScreeningChemical Biology & Drug Design, 2013
- Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme’s active site closureBMC Structural Biology, 2012
- The Original Michaelis Constant: Translation of the 1913 Michaelis–Menten PaperBiochemistry, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patientsClinical and Experimental Immunology, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPPBritish Journal of Haematology, 2008
- Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agentsBiochemical Pharmacology, 2007
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProceedings of the National Academy of Sciences, 2006